The DOI matches its Crossref record; 178 of the 178 references it cites were found in a registry or an index.
Cardiovascular Complications of Cancer Therapy
Open accessAbstract
Modern cancer therapy has successfully cured many cancers and converted a terminal illness to chronic disease. Because cancer patients often have co-existing heart diseases, expert advice from the cardiologists will improve clinical outcome. In addition, cancer therapy can also cause myocardial damage, induce endothelial dysfunction, and alter cardiac conduction. Thus, it is important for practicing cardiologists to be knowledgeable about the diagnosis, prevention, and management of cardiovascular complications of cancer therapy. In this first part of a 2-part review, we will review cancer therapy-induced cardiomyopathy and ischemia. This review is based on MEDLINE literature search, published clinical guidelines, and best practices in major cancer centers. With the number of cancer survivors expanding quickly, the time has come for cardiologists to work closely with cancer specialists to prevent and treat cancer therapy-induced cardiovascular complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Self-citationPlana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,504
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Self-citationBraunwald, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800239 · Cited by 1,257
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Anthracycline-Induced Cardiomyopathy
Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., Rubino, M., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.095 · Cited by 1,105
Geyer, H., Caracciolo, G., Abe, H., Wilansky, S., Carerj, S., Gentile, F., Nesser, H.-J., Khandheria, B., Narula, J., & Sengupta, P. P. (2010) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2010.02.015 · Cited by 1,102
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Thavendiranathan, P., Poulin, F., Lim, K.-D., Plana, J. C., Woo, A., & Marwick, T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.073 · Cited by 1,079
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 990
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3185 · Cited by 947
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H.-P., Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 938
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
WRITING COMMITTEE MEMBERS, Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G., Fonarow, G. C., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000435 · Cited by 897
Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
Zethelius, B., Berglund, L., Sundström, J., Ingelsson, E., Basu, S., Larsson, A., Venge, P., & Ärnlöv, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707064 · Cited by 889
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Self-citationSawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.035 · Cited by 689
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Walko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 657
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 635
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 563
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Galectin-3: A Novel Mediator of Heart Failure Development and Progression
de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp097 · Cited by 524
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Perk, G., Tunick, P. A., & Kronzon, I. (2007) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2006.08.023 · Cited by 501
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
Gottdiener, J. S. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.141.6.758 · Cited by 486
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
Echocardiographic Assessment of Myocardial Strain
Gorcsan, J., & Tanaka, H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.038 · Cited by 468
Katus, H. (1989) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(89)90680-9 · Cited by 461
Negishi, K., Negishi, T., Hare, J. L., Haluska, B. A., Plana, J. C., & Marwick, T. H. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.02.008 · Cited by 454
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.05.013 · Cited by 422
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Cardiotoxicity of cytotoxic drugs
Schimmel, K. J. M., Richel, D. J., van den Brink, R. B. A., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.003 · Cited by 391
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics
Chen, M. H., Kerkelä, R., & Force, T. (2008) · Circulation · doi:10.1161/circulationaha.108.776831 · Cited by 379
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Trastuzumab‐associated cardiotoxicity
Keefe, D. L. (2002) · Cancer · doi:10.1002/cncr.10854 · Cited by 358
Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L., Rajangam, K., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.089334 · Cited by 347
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.033 · Cited by 340
Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3404 · Cited by 323
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Bird, B. R. J. H., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 307
Kozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0071 · Cited by 305
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.020 · Cited by 288
Clinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
Aminkeng, F., Bhavsar, A. P., Visscher, H., Rassekh, S. R., Li, Y., Lee, J. W., Brunham, L. R., Caron, H. N., van Dalen, E. C., Kremer, L. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3374 · Cited by 278
Ezaz, G., Long, J. B., Gross, C. P., & Chen, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000472 · Cited by 276
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Schuchter, L. M., Hensley, M. L., Meropol, N. J., & Winer, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.178 · Cited by 262
Skates, S. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.955 · Cited by 256
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Abdel-Qadir, H., Ethier, J.-L., Lee, D. S., Thavendiranathan, P., & Amir, E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.002 · Cited by 251
Ho, E., Brown, A., Barrett, P., Morgan, R. B., King, G., Kennedy, M. J., & Murphy, R. T. (2010) · Heart · doi:10.1136/hrt.2009.173997 · Cited by 242
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn168 · Cited by 237
Salzer, W. L., Devidas, M., Carroll, W. L., Winick, N., Pullen, J., Hunger, S. P., & Camitta, B. A. (2010) · Leukemia · doi:10.1038/leu.2009.261 · Cited by 235
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
Aminkeng, F., Ross, C. J. D., Rassekh, S. R., Hwang, S., Rieder, M. J., Bhavsar, A. P., Smith, A., Sanatani, S., Gelmon, K. A., Bernstein, D., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13008 · Cited by 234
Treatment-related cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Cochran, T. R., Franco, V. I., & Miller, T. L. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.195 · Cited by 233
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
Jensen, S. A., & Sørensen, J. B. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0178-1 · Cited by 232
Virani, S. A., Dent, S., Brezden-Masley, C., Clarke, B., Davis, M. K., Jassal, D. S., Johnson, C., Lemieux, J., Paterson, I., Sebag, I. A., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.078 · Cited by 231
Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8566 · Cited by 229
Keller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.157 · Cited by 214
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.09.001 · Cited by 207
Meinardi, M. T., van Veldhuisen, D. J., Gietema, J. A., Dolsma, W. V., Boomsma, F., van den Berg, M. P., Volkers, C., Haaksma, J., de Vries, E. G. E., Sleijfer, D. T., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2746 · Cited by 207
Marty, M., Espié, M., Llombart, A., Monnier, A., Rapoport, B. L., & Stahalova, V. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj134 · Cited by 202
Multiple Biomarkers for Risk Prediction in Chronic Heart Failure
Ky, B., French, B., Levy, W. C., Sweitzer, N. K., Fang, J. C., Wu, A. H. B., Goldberg, L. R., Jessup, M., & Cappola, T. P. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.111.965020 · Cited by 201
Jaffe, A. S., Landt, Y., Parvin, C. A., Abendschein, D. R., Geltman, E. M., & Ladenson, J. H. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.11.1770 · Cited by 197
A reassessment of cardiac toxicity associated with Taxol.
Arbuck, S. G., Strauss, W. H., Rowinsky, E. K., Christian, M. C., Suffness, M., Adams, J., Oakes, M., McGuire, W. P., Reed, E., & Gibbs, H. H. (1993) · PubMed · Cited by 195
Cardiac Function in 5-Year Survivors of Childhood Cancer: A Long-term Follow-up Study
van der Pal, H. J., van Dalen, E. C., Hauptmann, M., Kok, W. E., Caron, H. N., van den Bos, C., Oldenburger, F., Koning, C. C., van Leeuwen, F. E., & Kremer, L. C. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.233 · Cited by 191
Poole, C. J., Earl, H. M., Hiller, L., Dunn, J. A., Bathers, S., Grieve, R. J., Spooner, D. A., Agrawal, R. K., Fernando, I. N., Brunt, A. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052084 · Cited by 190
Iliescu, C. A., Grines, C. L., Herrmann, J., Yang, E. H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K. P., Leesar, M. A., & Marmagkiolis, K. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26379 · Cited by 190
Chintalgattu, V., Ai, D., Langley, R. R., Zhang, J., Bankson, J. A., Shih, T. L., Reddy, A. K., Coombes, K. R., Daher, I. N., Pati, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39434 · Cited by 188
Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.
Rezkalla, S., Kloner, R. A., Ensley, J., al-Sarraf, M., Revels, S., Olivenstein, A., Bhasin, S., Kerpel-Fronious, S., & Turi, Z. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.509 · Cited by 187
Iliescu, C., Grines, C. L., Herrmann, J., Yang, E. H., Cilingiroglu, M., Charitakis, K., Hakeem, A., Toutouzas, K., Leesar, M. A., & Marmagkiolis, K. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26375 · Cited by 186
Elevated B-type natriuretic peptide levels after anthracycline administration
Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., Kurabayashi, M., Yamaoki, K., Mitani, K., Hirai, H., et al. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.89908 · Cited by 185
Richards, C. J., Je, Y., Schutz, F. A. B., Heng, D. Y. C., Dallabrida, S. M., Moslehi, J. J., & Choueiri, T. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4309 · Cited by 180
Gelmon, K. A., Boyle, F. M., Kaufman, B., Huntsman, D. G., Manikhas, A., Di Leo, A., Martin, M., Schwartzberg, L. S., Lemieux, J., Aparicio, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.9590 · Cited by 178
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Lipshultz, S. E., Miller, T. L., Lipsitz, S. R., Neuberg, D. S., Dahlberg, S. E., Colan, S. D., Silverman, L. B., Henkel, J. M., Franco, V. I., Cushman, L. L., et al. (2012) · Pediatrics · doi:10.1542/peds.2012-0727 · Cited by 175
Dodos, F., Halbsguth, T., Erdmann, E., & Hoppe, U. C. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0633-6 · Cited by 174
Swain, S. M., Ewer, M. S., Cortés, J., Amadori, D., Miles, D., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Baselga, J. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0448 · Cited by 163
Symptomatic Cardiotoxicity Associated with 5‐Fluorouracil
Meyer, C. C., Calis, K. A., Burke, L. B., Walawander, C. A., & Grasela, T. H. (1997) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03748.x · Cited by 162
5-Fluorouracil cardiotoxicity.
Lomeo, A. M., Avolio, C., Iacobellis, G., & Manzione, L. (1990) · PubMed · Cited by 157
Swain, S. M., & Vici, P. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0498-7 · Cited by 155
Cutsem, E. V., Hoff, P. M., Blum, J., Abt, M., & Osterwalder, B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf108 · Cited by 149
Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity
Chicco, A. J., Hydock, D. S., Schneider, C. M., & Hayward, R. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00148.2005 · Cited by 144
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction
Quezado, Z., Wilson, W. H., Cunnion, R. E., Parker, M. M., Reda, D., Bryant, G., & Ognibene, F. P. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00006 · Cited by 144
Balk, E. M., Ioannidis, J. P. A., Salem, D. N., Chew, P. W., & Lau, J. (2001) · Annals of Emergency Medicine · doi:10.1067/mem.2001.114905 · Cited by 140
Daugaard, G., Lassen, U., Bie, P., et al. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.03.009 · Cited by 139
Oncocardiology—Past, Present, and Future
Yeh, E. T. H., & Chang, H. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2132 · Cited by 134
Self-citationOnitilo, A. A., Engel, J. M., Stankowski, R. V., Liang, H., Berg, R. L., & Doi, S. A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2039-z · Cited by 133
Grandin, E. W., Ky, B., Cornell, R. F., Carver, J. R., & Lenihan, D. J. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.11.008 · Cited by 132
Anand, A. J. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800314 · Cited by 132
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
Lenihan, D. J., Suter, T. M., Brammer, M. G., Neate, C., Ross, G. A., & Baselga, J. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr294 · Cited by 120
Heart Failure Induced by Non-Cardiac Drugs
rdal, L. S., & Spigset, O. (2006) · Drug Safety · doi:10.2165/00002018-200629070-00003 · Cited by 119
Vrooman, L. M., Neuberg, D. S., Stevenson, K. E., Asselin, B. L., Athale, U. H., Clavell, L. A., Cole, P. D., Kelly, K. M., Larsen, E. C., Laverdière, C., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.022 · Cited by 116
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub3 · Cited by 113
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib
Hacıhanefioğlu, A., Tarkun, P., & Gonullu, E. O. (2008) · International Journal of Hematology · doi:10.1007/s12185-008-0139-7 · Cited by 108
van Dalen, E. C., van der Pal, H. J. H., & Kremer, L. C. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005008.pub4 · Cited by 103
Jensen, S. A., & Sørensen, J. B. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1669-x · Cited by 100
Polyethylene Glycol-Liposomal Doxorubicin
Sharpe, M., Easthope, S. E., Keating, G. M., & Lamb, H. M. (2002) · Drugs · doi:10.2165/00003495-200262140-00012 · Cited by 96
5-Fluorouracil–Induced Coronary Vasospasm
Shoemaker, L. K., Arora, U. K., & Lima, C. M. R. (2004) · Cancer Control · doi:10.1177/107327480401100107 · Cited by 85
Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt, G., Dørup, I., Sørensen, K. E., & Sullivan, I. D. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04803.x · Cited by 84
Seymour, L., Bramwell, V., & Moran, L. A. (1999) · PubMed · Cited by 78
Dranitsaris, G., Rayson, D., Vincent, M. D., Chang, J., Gelmon, K. A., Sandor, D. W., & Reardon, G. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9803-5 · Cited by 78
Smith, D. H., Adams, J. R., Johnston, S. R. D., Gordon, A., Drummond, M., & Bennett, C. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf275 · Cited by 76
Screening for Cardiac Dysfunction in Anthracycline-Exposed Childhood Cancer Survivors
Armenian, S. H., Gelehrter, S. K., Vase, T., Venkatramani, R., Landier, W., Wilson, K. D., Herrera, C., Reichman, L., Menteer, J.-D., Mascarenhas, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3490 · Cited by 75
Reversible Cardiomyopathy Associated with Sunitinib and Sorafenib
Uraizee, I., Cheng, S. C., & Moslehi, J. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1108849 · Cited by 71
Pichon, M.-F., Cvitkovic, F., Hacène, K., Delaunay, J., Lokiec, F. M., Collignon, M. A., & Pecking, A. P. (2005) · PubMed · Cited by 71
Coronary spasm induced by capecitabine
Schnetzler, B., Popova, N., Lamb, C. C., & Sappino, A. P. (2001) · Annals of Oncology · doi:10.1023/a:1011152931300 · Cited by 60
Chen-Scarabelli, C. A., Corsetti, G., Pasini, E., Dioguardi, F. S., Sahni, G., Narula, J., Gavazzoni, M., Patel, H., Saravolatz, L. I. I., Knight, R. A., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.024 · Cited by 57
Self-citationTrastuzumab versus lapatinib: The cardiac side of the story
Azim, H. A., Azim, H. A., & Escudier, B. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.06.007 · Cited by 55
Galfrascoli, E., Piva, S., Cinquini, M., Rossi, A., Verde, N. M. L., Bramati, A., Moretti, A., Manazza, A. D., Damia, G. L. M., Torri, V., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.10.010 · Cited by 51
Li, X., Xu, S., Tan, Y., & Chen, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010432.pub2 · Cited by 50
Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity
Lee, H. S., Son, C. B., Shin, S. H., & Kim, Y. S. (2008) · Cancer Research and Treatment · doi:10.4143/crt.2008.40.3.121 · Cited by 48
Maurea, N., Spallarossa, P., Dessalvi, C. C., Madonna, R., Mele, D., Monte, I. P., Novo, G., Pagliaro, P., Pepe, A., Tocchetti, C. G., et al. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000383 · Cited by 41
Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers
Gupta‐Malhotra, M., Steinherz, P. G., Cheung, N. V., & Steinherz, L. J. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10298 · Cited by 39
Al-Batran, S.-E., Güntner, M., Pauligk, C., Scholz, M., Chen, R., Beiss, B. K., Stopatschinskaja, S., Lerbs, W., Harbeck, N., & Jäger, E. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605961 · Cited by 35
Bortezomib-Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma
Gupta, A. K., Pandey, A., & Sethi, S. (2011) · Cardiovascular Toxicology · doi:10.1007/s12012-011-9146-7 · Cited by 33
McArthur, H. L., Rugo, H. S., Nulsen, B., Hawks, L. C., Grothusen, J., Melisko, M., Moasser, M. M., Paulson, M., Traina, T. A., Patil, S. N., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1969 · Cited by 28
Cardiomyopathy Associated With Cancer Therapy
Yu, A. F., Steingart, R. M., & Fuster, V. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.08.004 · Cited by 25
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents
Escalante, C. P., Chang, Y.-C., Liao, K.-P. E., Rouleau, T., Halm, J. K., Bossi, P., Bhadriraju, S., Brito-Dellan, N., Sahai, S. K., Yusuf, S. W., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3310-3 · Cited by 25
Bortezomib-induced Severe Congestive Heart Failure
Jerkins, J. H. (2010) · Cardiology Research · doi:10.4021/cr105e · Cited by 18
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Strongman, H., Gadd, S., Matthews, A., Mansfield, K. E., Stanway, S., Lyon, A. R., dos-Santos-Silva, I., Smeeth, L., & Bhaskaran, K. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31674-5 · Cited by 509
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N. O., Albuquerque, D. C. D., Rassi, S., Colafranceschi, A. S., Freitas Junior, A. F. D., Ferraz, A. S., Biolo, A., et al. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180190 · Cited by 377
Metadata
- Authors
- Chang, H.-M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., & Yeh, E. T. H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 70
- Issue
- 20
- Pages
- 2536-2551
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2769699235
- Cited by
- 385
- References
- 178
- FWCI
- 23.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.